EW 126.92 Edwards Lifesciences Corp $EW Hit a 52 week high of 126.86 Closing the day 09:44 at 126.92 +0.69 +0.55% With a day low of 126.05 and a total volume of 44,836.
EW Recent Posts: http://investorshangout.com/Edwards-Lifescien...-EW-50936/
EW Edwards Lifesciences Corp Recent Headline News
Watch for Edwards Lifesciences to Potentially Pullback After Gaining 1.39% Yesterday
Comtex SmarTrend(R) - Mon Nov 17, 5:31PM CST
Edwards Lifesciences (NYSE:EW) traded in a range yesterday that spanned from a low of $124.35 to a high of $126.62. Yesterday, the shares gained 1.4%, which took the trading range above the 3-day high of $124.94 on volume of 696,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
EW: 126.94 (+0.71)
Teleflex (TFX) Hits 52-Week High on Strong Q3 Results - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Nov 17, 12:20PM CST
In the recently reported third-quarter 2014, Telefex Incorporated (TFX) posted double-digit year-over-year revenue and adjusted earnings growth.
FLDM: 30.76 (+0.75), EW: 126.94 (+0.71), TFX: 115.47 (+0.19), ANGO: 16.75 (-0.10)
Varian Medical (VAR) Down to Strong Sell on Dismal Q3 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Nov 14, 2:20PM CST
On Nov 14, 2014, Zacks Investment Research downgraded Varian Medical Systems (VAR) to a Zacks Rank #5 (Strong Sell).
ABMD: 33.78 (+0.02), VAR: 88.30 (+0.69), EW: 126.94 (+0.71), ANGO: 16.75 (-0.10)
Edwards Lifesciences Up 16.5% Since SmarTrend Uptrend Call (EW)
Comtex SmarTrend(R) - Fri Nov 14, 9:46AM CST
SmarTrend identified an Uptrend for Edwards Lifesciences (NYSE:EW) on October 23rd, 2014 at $106.16. In approximately 3 weeks, Edwards Lifesciences has returned 16.53% as of today's recent price of $123.70.
EW: 126.94 (+0.71)
Nicholas Valeriani Appointed To Edwards Lifesciences' Board Of Directors
PR Newswire - Fri Nov 14, 8:00AM CST
Edwards Lifesciences Corporation (NYSE: EW), the global leader in the science of heart valves and hemodynamic monitoring, today announced that Nicholas J. Valeriani has been appointed to its board of directors and will also serve as a member of its Compensation and Governance Committee. Since 2012, Valeriani, 58, has been the Chief Executive Officer of the Gary and Mary West Health Institute, an independent, nonprofit medical research organization that works to create new, more effective ways of delivering care at lower costs. Prior to joining West Health, Valeriani spent 34 years at Johnson & Johnson and served as a member of its executive committee.
JNJ: 109.01 (+0.71), EW: 126.94 (+0.71)
International Society for Cardiovascular Translational Research Governing Board Adds Medical Industry Leaders
PRWeb - Fri Nov 14, 5:02AM CST
The International Society for Cardiovascular Translational Research, 'ISCTR' announced today that the society's Governing Board has grown with the additions of Stanton J. Rowe, Edwards Lifesciences chief scientific officer and Dr. Charles Simonton, divisional vice president, Medical Affairs, chief medical officer, Abbott Vascular. Mr. Rowe and Dr. Simonton are both medical industry leaders and medical device development experts.
EW: 126.94 (+0.71)
Thoratec (THOR) Down to Strong Sell on Growing Headwinds - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Nov 12, 12:20PM CST
On Nov 11, 2014, Zacks Investment Research downgraded Thoratec Corp. (THOR) to a Zacks Rank #5 (Strong Sell).
ABMD: 33.78 (+0.02), EW: 126.94 (+0.71), THOR: 29.70 (+0.50), ANGO: 16.75 (-0.10)
Roka Bioscience (ROKA) in Focus: Stock Surges 19.3% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Nov 11, 8:11AM CST
Roka Bioscience, Inc. (ROKA) was a big mover last session, as the company saw its shares rise over 19% on the day.
ABMD: 33.78 (+0.02), ROKA: 3.87 (+0.12), EW: 126.94 (+0.71), ANGO: 16.75 (-0.10)
Global Prosthetic Heart Valves Industry
PR Newswire - Mon Nov 10, 5:55PM CST
This report analyzes the worldwide markets for Prosthetic Heart Valves in US$ Million by the following Product Segments: Mechanical valves, and Biological/Tissue valves. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World. Annual estimates and forecasts are provided for the period 2013 through 2020. Also, a seven-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. The report profiles 22 companies including many key and niche players such as -
EW: 126.94 (+0.71)
After Yesterday's Rally of 1.50% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Mon Nov 10, 5:12PM CST
Edwards Lifesciences (NYSE:EW) traded in a range yesterday that spanned from a low of $122.73 to a high of $124.60. Yesterday, the shares gained 1.5%, which took the trading range above the 3-day high of $123.68 on volume of 681,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
EW: 126.94 (+0.71)
Volcano Posts Narrower-than-Expected Q3 Loss, Guides Low - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Nov 10, 10:10AM CST
Despite Volcano (VOLC) provided disappointing revenue guidance for 2014 on account of expected negative foreign exchange impact, management expects accelerated profitability over the near term.
ABMD: 33.78 (+0.02), VOLC: 11.17 (+0.09), EW: 126.94 (+0.71), ANGO: 16.75 (-0.10)
Strength Seen in DexCom (DXCM): Stocks Gains 14.1% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Nov 10, 8:46AM CST
DexCom (DXCM) was a big mover last session, with shares rising over 14% on the day.
ABMD: 33.78 (+0.02), DXCM: 51.56 (-0.18), EW: 126.94 (+0.71), ANGO: 16.75 (-0.10)
Earnings Flashback: Since Reporting Quarterly Results 2 Weeks Ago Edwards Lifesciences Is Up 16.7% (EW)
Comtex SmarTrend(R) - Mon Nov 10, 8:09AM CST
Two weeks ago on October 23rd, 2014 Edwards Lifesciences (NYSE:EW) reported earnings and analysts, on average, expected earnings of $0.72 on sales of $546.0 million. Edwards Lifesciences actually reported earnings of $0.80 per share on sales of $607.4 million, beating EPS estimates by $0.08 and beating revenue estimates by $61.4 million. Shares of Edwards Lifesciences have climbed from $105.19 to $122.76, representing a gain of 16.7% since the company reported earnings 18 days ago.
EW: 126.94 (+0.71)
Edwards Lifesciences To Present At Credit Suisse 2014 Healthcare Conference
PR Newswire - Fri Nov 07, 12:59PM CST
Edwards Lifesciences Corporation (NYSE: EW), the global leader in the science of heart valves and hemodynamic monitoring, is scheduled to present at the Credit Suisse 2014 Healthcare Conference at the Arizona Biltmore in Phoenix on Tuesday, November 11, 2014.
EW: 126.94 (+0.71)
Shares of EW Up 15.3% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Fri Nov 07, 9:17AM CST
SmarTrend identified an Uptrend for Edwards Lifesciences (NYSE:EW) on October 23rd, 2014 at $106.16. In approximately 2 weeks, Edwards Lifesciences has returned 15.30% as of today's recent price of $122.40.
EW: 126.94 (+0.71)
Downgrade Alert for Edwards Lifesciences (EW)
Comtex SmarTrend(R) - Fri Nov 07, 6:57AM CST
Edwards Lifesciences (NYSE:EW) was downgraded from Buy to Neutral at Sterne Agee today. The stock closed yesterday at $123.57 on volume of 784,000 shares, below average daily volume of 936,000. Edwards Lifesciences share prices have moved between a 52-week high of $123.68 and a 52-week low of $60.62 and closed yesterday at 104% above that low price at $123.57 per share. Over the last five market days, the 200-day moving average (MA) has gone up 1.2% while the 50-day MA has advanced 1.8%.
EW: 126.94 (+0.71)
Insider Trading Alert - EW, SLAB And LCI Traded By Insiders
at The Street - Thu Oct 30, 10:45AM CDT
Stocks with insider trader activity include EW, SLAB and LCI
LCI: 46.96 (+0.32), SLAB: 45.33 (+0.79), EW: 126.94 (+0.71)
Look for Shares of Edwards Lifesciences to Potentially Pullback after Yesterday's 1.45% Rise
Comtex SmarTrend(R) - Wed Oct 29, 4:26PM CDT
Edwards Lifesciences (NYSE:EW) traded in a range yesterday that spanned from a low of $118.01 to a high of $120.12. Yesterday, the shares gained 1.5%, which took the trading range above the 3-day high of $118.84 on volume of 1.4 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
EW: 126.94 (+0.71)
Compliance Notice, Dividend Announcements, New Share Repurchase Program, and Financial Results - Research Reports on Gilead, Pfizer, AbbVie, Edwards and Lilly
PR Newswire - Wed Oct 29, 7:35AM CDT
Today, Analysts Review released its research reports regarding Gilead Sciences, Inc. (NASDAQ: GILD), Pfizer Inc. (NYSE: PFE), AbbVie Inc. (NYSE: ABBV), Edwards Lifesciences Corp. (NYSE: EW) and Eli Lilly and Co. (NYSE: LLY). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/7520-100free.
GILD: 102.12 (+1.68), PFE: 30.49 (+0.17), EW: 126.94 (+0.71), LLY: 67.91 (+0.62), ABBV: 65.73 (+0.69)
IDEXX Tops Q3 Earnings and Revenues; Guidance Revised - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Oct 28, 12:10PM CDT
Since the news release, IDEXX's (IDXX) share price has climbed 9.8% to eventually close at $138.76 yesterday.
ATEC: 1.39 (+0.01), EW: 126.94 (+0.71), IDXX: 150.55 (+1.14), ANGO: 16.75 (-0.10)
EW Recent Posts: http://investorshangout.com/Edwards-Lifescien...-EW-50936/
EW Edwards Lifesciences Corp Recent Headline News
Watch for Edwards Lifesciences to Potentially Pullback After Gaining 1.39% Yesterday
Comtex SmarTrend(R) - Mon Nov 17, 5:31PM CST
Edwards Lifesciences (NYSE:EW) traded in a range yesterday that spanned from a low of $124.35 to a high of $126.62. Yesterday, the shares gained 1.4%, which took the trading range above the 3-day high of $124.94 on volume of 696,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
EW: 126.94 (+0.71)
Teleflex (TFX) Hits 52-Week High on Strong Q3 Results - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Nov 17, 12:20PM CST
In the recently reported third-quarter 2014, Telefex Incorporated (TFX) posted double-digit year-over-year revenue and adjusted earnings growth.
FLDM: 30.76 (+0.75), EW: 126.94 (+0.71), TFX: 115.47 (+0.19), ANGO: 16.75 (-0.10)
Varian Medical (VAR) Down to Strong Sell on Dismal Q3 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Nov 14, 2:20PM CST
On Nov 14, 2014, Zacks Investment Research downgraded Varian Medical Systems (VAR) to a Zacks Rank #5 (Strong Sell).
ABMD: 33.78 (+0.02), VAR: 88.30 (+0.69), EW: 126.94 (+0.71), ANGO: 16.75 (-0.10)
Edwards Lifesciences Up 16.5% Since SmarTrend Uptrend Call (EW)
Comtex SmarTrend(R) - Fri Nov 14, 9:46AM CST
SmarTrend identified an Uptrend for Edwards Lifesciences (NYSE:EW) on October 23rd, 2014 at $106.16. In approximately 3 weeks, Edwards Lifesciences has returned 16.53% as of today's recent price of $123.70.
EW: 126.94 (+0.71)
Nicholas Valeriani Appointed To Edwards Lifesciences' Board Of Directors
PR Newswire - Fri Nov 14, 8:00AM CST
Edwards Lifesciences Corporation (NYSE: EW), the global leader in the science of heart valves and hemodynamic monitoring, today announced that Nicholas J. Valeriani has been appointed to its board of directors and will also serve as a member of its Compensation and Governance Committee. Since 2012, Valeriani, 58, has been the Chief Executive Officer of the Gary and Mary West Health Institute, an independent, nonprofit medical research organization that works to create new, more effective ways of delivering care at lower costs. Prior to joining West Health, Valeriani spent 34 years at Johnson & Johnson and served as a member of its executive committee.
JNJ: 109.01 (+0.71), EW: 126.94 (+0.71)
International Society for Cardiovascular Translational Research Governing Board Adds Medical Industry Leaders
PRWeb - Fri Nov 14, 5:02AM CST
The International Society for Cardiovascular Translational Research, 'ISCTR' announced today that the society's Governing Board has grown with the additions of Stanton J. Rowe, Edwards Lifesciences chief scientific officer and Dr. Charles Simonton, divisional vice president, Medical Affairs, chief medical officer, Abbott Vascular. Mr. Rowe and Dr. Simonton are both medical industry leaders and medical device development experts.
EW: 126.94 (+0.71)
Thoratec (THOR) Down to Strong Sell on Growing Headwinds - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Nov 12, 12:20PM CST
On Nov 11, 2014, Zacks Investment Research downgraded Thoratec Corp. (THOR) to a Zacks Rank #5 (Strong Sell).
ABMD: 33.78 (+0.02), EW: 126.94 (+0.71), THOR: 29.70 (+0.50), ANGO: 16.75 (-0.10)
Roka Bioscience (ROKA) in Focus: Stock Surges 19.3% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Nov 11, 8:11AM CST
Roka Bioscience, Inc. (ROKA) was a big mover last session, as the company saw its shares rise over 19% on the day.
ABMD: 33.78 (+0.02), ROKA: 3.87 (+0.12), EW: 126.94 (+0.71), ANGO: 16.75 (-0.10)
Global Prosthetic Heart Valves Industry
PR Newswire - Mon Nov 10, 5:55PM CST
This report analyzes the worldwide markets for Prosthetic Heart Valves in US$ Million by the following Product Segments: Mechanical valves, and Biological/Tissue valves. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World. Annual estimates and forecasts are provided for the period 2013 through 2020. Also, a seven-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. The report profiles 22 companies including many key and niche players such as -
EW: 126.94 (+0.71)
After Yesterday's Rally of 1.50% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Mon Nov 10, 5:12PM CST
Edwards Lifesciences (NYSE:EW) traded in a range yesterday that spanned from a low of $122.73 to a high of $124.60. Yesterday, the shares gained 1.5%, which took the trading range above the 3-day high of $123.68 on volume of 681,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
EW: 126.94 (+0.71)
Volcano Posts Narrower-than-Expected Q3 Loss, Guides Low - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Nov 10, 10:10AM CST
Despite Volcano (VOLC) provided disappointing revenue guidance for 2014 on account of expected negative foreign exchange impact, management expects accelerated profitability over the near term.
ABMD: 33.78 (+0.02), VOLC: 11.17 (+0.09), EW: 126.94 (+0.71), ANGO: 16.75 (-0.10)
Strength Seen in DexCom (DXCM): Stocks Gains 14.1% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Nov 10, 8:46AM CST
DexCom (DXCM) was a big mover last session, with shares rising over 14% on the day.
ABMD: 33.78 (+0.02), DXCM: 51.56 (-0.18), EW: 126.94 (+0.71), ANGO: 16.75 (-0.10)
Earnings Flashback: Since Reporting Quarterly Results 2 Weeks Ago Edwards Lifesciences Is Up 16.7% (EW)
Comtex SmarTrend(R) - Mon Nov 10, 8:09AM CST
Two weeks ago on October 23rd, 2014 Edwards Lifesciences (NYSE:EW) reported earnings and analysts, on average, expected earnings of $0.72 on sales of $546.0 million. Edwards Lifesciences actually reported earnings of $0.80 per share on sales of $607.4 million, beating EPS estimates by $0.08 and beating revenue estimates by $61.4 million. Shares of Edwards Lifesciences have climbed from $105.19 to $122.76, representing a gain of 16.7% since the company reported earnings 18 days ago.
EW: 126.94 (+0.71)
Edwards Lifesciences To Present At Credit Suisse 2014 Healthcare Conference
PR Newswire - Fri Nov 07, 12:59PM CST
Edwards Lifesciences Corporation (NYSE: EW), the global leader in the science of heart valves and hemodynamic monitoring, is scheduled to present at the Credit Suisse 2014 Healthcare Conference at the Arizona Biltmore in Phoenix on Tuesday, November 11, 2014.
EW: 126.94 (+0.71)
Shares of EW Up 15.3% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Fri Nov 07, 9:17AM CST
SmarTrend identified an Uptrend for Edwards Lifesciences (NYSE:EW) on October 23rd, 2014 at $106.16. In approximately 2 weeks, Edwards Lifesciences has returned 15.30% as of today's recent price of $122.40.
EW: 126.94 (+0.71)
Downgrade Alert for Edwards Lifesciences (EW)
Comtex SmarTrend(R) - Fri Nov 07, 6:57AM CST
Edwards Lifesciences (NYSE:EW) was downgraded from Buy to Neutral at Sterne Agee today. The stock closed yesterday at $123.57 on volume of 784,000 shares, below average daily volume of 936,000. Edwards Lifesciences share prices have moved between a 52-week high of $123.68 and a 52-week low of $60.62 and closed yesterday at 104% above that low price at $123.57 per share. Over the last five market days, the 200-day moving average (MA) has gone up 1.2% while the 50-day MA has advanced 1.8%.
EW: 126.94 (+0.71)
Insider Trading Alert - EW, SLAB And LCI Traded By Insiders
at The Street - Thu Oct 30, 10:45AM CDT
Stocks with insider trader activity include EW, SLAB and LCI
LCI: 46.96 (+0.32), SLAB: 45.33 (+0.79), EW: 126.94 (+0.71)
Look for Shares of Edwards Lifesciences to Potentially Pullback after Yesterday's 1.45% Rise
Comtex SmarTrend(R) - Wed Oct 29, 4:26PM CDT
Edwards Lifesciences (NYSE:EW) traded in a range yesterday that spanned from a low of $118.01 to a high of $120.12. Yesterday, the shares gained 1.5%, which took the trading range above the 3-day high of $118.84 on volume of 1.4 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
EW: 126.94 (+0.71)
Compliance Notice, Dividend Announcements, New Share Repurchase Program, and Financial Results - Research Reports on Gilead, Pfizer, AbbVie, Edwards and Lilly
PR Newswire - Wed Oct 29, 7:35AM CDT
Today, Analysts Review released its research reports regarding Gilead Sciences, Inc. (NASDAQ: GILD), Pfizer Inc. (NYSE: PFE), AbbVie Inc. (NYSE: ABBV), Edwards Lifesciences Corp. (NYSE: EW) and Eli Lilly and Co. (NYSE: LLY). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/7520-100free.
GILD: 102.12 (+1.68), PFE: 30.49 (+0.17), EW: 126.94 (+0.71), LLY: 67.91 (+0.62), ABBV: 65.73 (+0.69)
IDEXX Tops Q3 Earnings and Revenues; Guidance Revised - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Oct 28, 12:10PM CDT
Since the news release, IDEXX's (IDXX) share price has climbed 9.8% to eventually close at $138.76 yesterday.
ATEC: 1.39 (+0.01), EW: 126.94 (+0.71), IDXX: 150.55 (+1.14), ANGO: 16.75 (-0.10)
